Lassa Fever Death Toll in Nigeria Rises to 190

The death toll from Lassa fever in Nigeria has risen to 190 as of May 12, 2026. This increase highlights the ongoing public health challenge posed by the zoonotic viral hemorrhagic fever, which remains endemic in several regions of the country.

The Nigeria Centre for Disease Control (NCDC) is the primary body tracking the outbreak, managing the identification of cases and the deployment of medical resources. The rise in fatalities underscores the difficulty of early detection and the critical need for rapid intervention in affected communities.

Lassa fever is caused by the Lassa virus, a member of the Arenaviridae family. It is primarily transmitted to humans through contact with food or household items contaminated with the urine or feces of infected multimammate rats, known scientifically as Mastomys natalensis.

Once the virus enters the human body, it can cause a range of symptoms that often begin with a gradual onset of fever, general malaise, and headache. Because these initial signs are non-specific, the disease is frequently mistaken for malaria or other common febrile illnesses, which can delay life-saving treatment.

As the infection progresses, patients may experience sore throat, muscle pain, chest pain, nausea, vomiting, and diarrhea. In severe cases, the virus can lead to facial swelling, fluid accumulation in the lungs, and bleeding from the mouth, nose, or eyes.

One of the most significant long-term complications of Lassa fever is sensorineural hearing loss. This symptom occurs in a substantial percentage of survivors, regardless of the severity of the initial illness, and is often permanent.

Medical management of the virus relies heavily on the administration of Ribavirin, an antiviral medication. Clinical data indicates that Ribavirin is most effective when administered early in the course of the infection, which makes rapid diagnosis essential for survival.

However, the efficacy of the treatment is often hindered by the lack of diagnostic facilities in rural areas. Many patients only reach tertiary health centers after the virus has already caused significant organ damage or entered the hemorrhagic phase.

Public Health Prevention and Control

Preventing Lassa fever requires a combination of environmental management and behavioral changes to break the chain of transmission between rodents and humans. Public health officials emphasize the importance of rodent control within residential areas.

Key preventative measures recommended by health authorities include:

• Storing food in rodent-proof containers to prevent contamination.
• Maintaining high standards of hygiene in kitchens and dining areas.
• Avoiding the practice of drying food items on the ground where rodents can access them.
• Implementing community-wide rodent control programs to reduce the population of the Mastomys rat.

The NCDC and the World Health Organization (WHO) promote a One Health approach to combat the virus. This strategy integrates human, animal, and environmental health surveillance to better predict and manage outbreaks.

By monitoring rodent populations and environmental triggers, health agencies aim to identify high-risk zones before human cases spike. This proactive surveillance is intended to allow for the preemptive distribution of resources and public awareness campaigns.

Challenges in Containment

Despite these efforts, containment remains difficult due to the wide geographical distribution of the reservoir host. The multimammate rat is found across much of West Africa, making the risk of infection a persistent reality for millions of people.

the seasonal nature of the disease often sees a peak during the dry season. This pattern is believed to be linked to rodent migration into human dwellings in search of food and shelter as their natural habitats dry up.

The current death toll of 190 as of May 12, 2026, reflects the complexities of managing a disease that intersects with socioeconomic factors, such as housing quality and food security. Improving rural healthcare infrastructure remains a primary goal for reducing the case-fatality rate.

Efforts are ongoing to develop more accessible and rapid diagnostic tests that can be used at the point of care. Such advancements would allow clinicians to begin Ribavirin treatment hours or days earlier than is currently possible in many parts of Nigeria.